| Expression pattern: |
UP |
| Associated gene: |
SGK1, eIF4A3, LEF1, AGO2 |
| Associated microRNA: |
miR-133a-3p, miR-133b |
| Biological function: |
promotes enzalutamide resistance and decreases enzalutamide sensitivity; promotes cell proliferation/viability under enzalutamide treatment |
| Molecular mechanism: |
Acts as a ceRNA/miRNA sponge for miR-133a-3p and miR-133b to upregulate SGK1; biogenesis promoted by eIF4A3 (binding flanking pre-mRNA) and LEF1 (transcriptionally regulates RAB3IP promoter). |
| Biological pathway or process: |
chemoresistance (promotes); proliferation (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
S
M
|
| Validation methods: |
Microarray; RNA-seq; RT-qPCR; divergent primers PCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; MTT; CCK8; Western Blot; ChIP / ChIP-seq; In Vivo Animal Model; Bioinformatics Analysis; Clinical Sample Validation |
| Clinical significance: |
circRAB3IP expression was significantly upregulated in EnzR PCa tissues compared with EnzS PCa tissues; higher in high grade PCa than low grade PCa or BPH |
| Description: |
circRAB3IP (hsa_circ_0000419), derived from RAB3IP, is upregulated in enzalutamide-resistant prostate cancer cells and tissues and promotes enzalutamide resistance. It mainly localizes to the cytoplasm and acts as a ceRNA by sponging miR-133a-3p/miR-133b to increase SGK1 expression; its expression/biogenesis is promoted by eIF4A3 and LEF1. |
| Confidence score: |
0.8575 |